During the forecast period, the global rabeprazole sodium market is expected to rise at a considerable CAGR. The market growth is being driven by the rising prevalence rate of gastroesophageal reflux diseases (GERD), duodenal ulcers, and other gut-related infections and diseases globally, which has surged the demand for better treatment options. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. Moreover, in 2019, the global prevalence of duodenal or peptic ulcer prevalence was approximately 8.09 million representing a 25.82% increase from 1990. The increase in the number of cigarette smokers, alcohol/tobacco consumers, and a significant increase in food habits are the major cause of these diseases. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.
Browse the full report description of “Global Rabeprazole Sodium Market Size, Share and Trends Analysis Report, By Type (Rabeprazole Sodium Monohydrate and Rabeprazole Sodium Crystalline), By Application (Gastroesophageal Reflux Disease Treatment, Duodenal Ulcer Treatment, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/rabeprazole-sodium-market
The prominent players in the market are focusing on acquisition and partnership collaboration with other market players to broaden their product offering in order to fulfill the growing market demand. For instance, in December 2021, Pfizer Inc. acquired Arena Pharmaceuticals, Inc along with its all the outstanding shares for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion, via a definitive agreement. Through this acquisition, the company acquired Arena’s portfolio which includes diverse and promising development-stage therapeutic candidates in gastroenterology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- including ASN Co., Intas Pharmaceutical Ltd., Pfizer Inc., Sandoz Inc. (Novartis International AG)), Teva Pharmaceutical Industries Ltd., and others.?
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Rabeprazole Sodium Market Report Segment
By Type
By Application
Global Rabeprazole Sodium Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/rabeprazole-sodium-market